This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Picks for the Week of February 5th
by Brian Bolan
Two Stocks That Have Attractive Qualities for Investors.
LabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.
AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up
by Zacks Equity Research
Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.
Phibro Animal (PAHC) Beats on Q2 Earnings, Raises Guidance
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q2.
Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid
by Zacks Equity Research
Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.
Top Ranked Growth Stocks to Buy for February 6th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 6th:
Bull Of The Day PetMed Express (PETS)
by Brian Bolan
A solid earnings report and a lawsuit dismissal could make the shorts turn tail on this stock.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4
by Zacks Equity Research
Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q4
by Zacks Equity Research
Omnicell's (OMCL) year-over-year growth at both the segments in Q4 is encouraging.
ABIOMED (ABMD) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
ABIOMED (ABMD) rides high on record revenues from Impella in third-quarter fiscal 2018. The company is also well poised with new accomplishments.
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
by Zacks Equity Research
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
Edwards Lifesciences (EW) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Edwards Lifesciences (EW) gains from strength in THVT on continued therapy adoption across all geographies in Q4.
Alibaba (BABA) Q3 Earnings Lag Estimates, Revenues Grow Y/Y
by Zacks Equity Research
Alibaba Group Holding Limited (BABA) fiscal third-quarter revenues driven by strong momentum in the company's New Retail strategy and expanding cloud business. Higher expenses hurt profits.
Alphabet (GOOGL) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Alphabet Inc. (GOOGL) delivers strong fourth quarter top line numbers on robust advertising and cloud revenues. However, increased expenditure on new activities impacted profits.
Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong
by Zacks Equity Research
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top
by Zacks Equity Research
In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.
Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.
McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View
by Zacks Equity Research
Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.
Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid
by Zacks Equity Research
Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.
IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.
Zacks.com highlights: PetMed Express, SINOPEC Shangai Petrochemical, NVR, Five Below and Gap
by Zacks Equity Research
Zacks.com highlights: PetMed Express, SINOPEC Shangai Petrochemical, NVR, Five Below and Gap
QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year growth in Q4 revenues is encouraging. Expansion in operating margin buoys optimism.
Why AWS is Important for Amazon's (AMZN) Earnings in Q4
by Zacks Equity Research
Amazon's (AMZN) fourth-quarter 2017 results are likely to benefit from AWS's dominant market position and expanding customer base.
5 DuPont-Tested Stocks for a Winning Portfolio
by Zacks Equity Research
Do you have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.
ResMed (RMD) Rides on Product Launches, Robust Global Growth
by Zacks Equity Research
ResMed's (RMD) product launches and strategies to gain traction in the sleep-disordered breathing market. This upside is further likely to drive the stock in the future.